December, 2019: A new patent application was filed with the USPTO. Glixn trademark was published and we are currently pursuing a Registered Trademark.
February, 2018: The USPTO announced that the BLOS# patent application will be allowed and a patent issued in the coming weeks.
July 11, 2017: The USPTO announced that the CAT-FISH method will be an issued patent on July 25, 2017. CAT-FISH is an example of another molecular biology based method co-invented and published in a peer-reviewed journal by Dr. Peter Stroot. The RiboSyn method is another example of a novel molecular biology based method that was published and patented.
Glixin is offering an opportunity for companies to participate in forthcoming clinical trials. Call John Kimber (720) 355-0446 for details.
March 16, 2017: Glixin (formerly HemaGnosis) has been invited to attend the 2017 BioBoot Camp Program April 20-21 in Denver, CO.
Glixin is currently seeking an investment of $3M to complete a clinical trial in Australia for the LifeStyle Choice BLOS# method. A Pitch Deck is provided below.